Discover
Lynparza (olaparib) / Merck (MSD), AstraZenecaROSY-O: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (clinicaltrials.gov) - Jun 9, 2020 - P3; N=124; Not yet recruiting; Sponsor: AstraZeneca
Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaClinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient (clinicaltrials.gov) - Jun 12, 2020 - P3; N=265; Active, not recruiting; Sponsor: Zai Lab (Shanghai) Co., Ltd.; Recruiting --> Active, not recruiting
mirvetuximab soravtansine (IMGN 853) / ImmunoGenFORWARD I: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 9, 2020 - P3; N=366; Completed; Sponsor: ImmunoGen, Inc.; Active, not recruiting --> Completed
Rubraca (rucaparib) / Clovis; Opdivo (nivolumab) / Ono Pharma, BMSClovis Oncology announces completion of target enrollment in the ATHENA trial, a phase 3 maintenance treatment study in front-line, newly-diagnosed advanced ovarian cancer (Clovis Oncology Press Release) - Jun 10, 2020 - "Clovis Oncology...announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca®(rucaparib)...and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO® (nivolumab), as front-line maintenance treatment of newly-diagnosed advanced ovarian cancer. ATHENA is the first front-line switch maintenance study designed to show PARP monotherapy and PARP/PD-1 combination therapy in one study design....Topline data for the Rubraca monotherapy versus placebo arm in all study populations is expected in the second half of 2021 and, if supportive, would serve as the basis of an sNDA for the maintenance treatment of front-line, newly-diagnosed, advanced ovarian cancer patients."
